KAHR KOL Webinar on CD47 Therapeutics: A Potential Treatment For Solid Tumor and Hematological Malignancies
| DATE: | December 2, 2021 |
|---|---|
| TIME: | 12:00 AM EST |
| LOCATION: | N/A |
About The Event
The webinar will feature presentations by Key Opinion Leaders (KOLs) Ezra Cohen, MD, FRCPSC, FASCO (UC San Diego Health) and Naval G. Daver, MD (MD Anderson Cancer Center).
- Dr. Cohen will provide an overview of the therapeutic potential of CD47 therapies for the treatment of solid tumors.
- Dr. Daver will discuss the unmet medical need in treating patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML, highlighting the space available for novel CD47 therapies in the current treatment landscape.
KAHR’s Chief Executive Officer, Yaron Pereg will discuss the company’s pipeline of drug candidates targeting multiple immune checkpoints with potential to treat a wide range of solid tumors and hematological malignancies. Chief Medical Officer, Dr. Adam Foley–Comer will discuss clinical data from the ongoing Phase I/II study in advanced solid tumors evaluating DSP107, KAHR’s lead anti–CD47 candidate. DSP107 targets CD47-overexpressing tumors, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal to activate tumor antigen-specific T-cells.
A Q&A session will follow the formal presentations.